Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
July 23rd, 2024
Chordia wins the Minister of Education, Culture, Sports,
Science and Technology Award at the Japan Startup Awards 2024.
Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the researchand development of novel therapies for cancer, was awarded the Minister of Education,Culture, Sports, Science and Technology Award at the "Japan Startup Awards 2024"
ceremony for its outstanding contribution to the effort on commercialization ofresearch results as a university-based startup.

(Left: Daisuke Morishita, CSO; Right: Masahito Moriyama, Minister ofEducation, Culture, Sports, Science and Technology)
As a start-up spin-out from major companies, we are developing new anti-cancer
drugs based on academic seeds discovered by Kyoto and Miyazaki Universities , withsupport from AMED and public-private fund iCAP. In 2020, MALT1 inhibitor CTX177 (ONO-7018) was out-licensed to Ono Pharmaceutical Company Ltd. and received
an upfront payment of ¥800 million and a first development payment of ¥2.5 billion.
In addition, we are entitled to receive up to 49.6 billion yen in milestone payments
based on future development progress and sales, as well as tiered royalties in the highsingle to low double digits based on worldwide sales. Through industry-governmentacademia collaborative research, we aim to create novel anti-cancer drugs and new

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

therapeutic options for cancer patients who still lack adequate treatment and contributeto the drug discovery ecosystem in Japan.

About the Japan Startup Awards
The Japan Startup Awards is a system to honor and celebrate entrepreneurs andstartups who have created impactful new businesses that will serve as role models forthe next generation. The purpose of the award is to promote the importance of taking
on challenges and the social recognition of entrepreneurs in general among people whoaspire to start their own businesses and society at large, thereby raising awareness ofentrepreneurship in society.
About Chordia Therapeutics
Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa, Japan,
developing novel cancer therapies. Chordia’s lead asset, CLK inhibitor CTX-712, iscurrently in Phase 1 clinical study in Japan and Phase1/2 clinical study in the US.
CTX-712 potentially targets vulnerabilities in cancer and could benefits patients withvarious types of cancer. In addition to CTX-712, Chordia is researching several
preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective
in cancers with specific abnormalities, as well as GCN2 inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, please contact to IR: ir@chordiatherapeutics.com